Castle Biosciences works with Medicare, commercial insurers and the physician’s institution to secure payment coverage for DecisionDx™-Melanoma on the patient’s behalf. The Company also has put in place a Patient Assistance Program with the belief that care should not be contingent on financial considerations.

Know Your Risk


A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation